Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Published on
Journal: Japanese Journal of Clinical Oncology
[저자] Wataru Munakata, Koji Izutsu, Yuko Mishima, Hirokazu Nagai, Yuko Ishihara, Junji Suzumiya, Yuzuru Kanakura, Toshihiro Nanki, Takeshi Miyake, Atsuko Kawasaki, Tatsuya Yoshinaga, Kenichi Ishizawa
[Category] 대상포진,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1093/jjco/hyad082    
[Article Type] Original Article
[Source] PMC

Single-agent mosunetuzumab demonstrates an acceptable safety profile and antitumor activity in Japanese patients with relapsed/refractory B-cell NHL and no new safety signals compared with the global Phase I study.

All Keywords
【저자키워드】 antibodies, Japan, administration, Non-Hodgkin Lymphoma, intravenous, bispecific/administration and dosage, bispecific/adverse effects,